Rongcheng Luo

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations

Hepatology, Medicine, Cancer Management +12

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai Shi, Li Zhang, Xiaoqing Liu et al. · The Lancet Oncology · 2013 · 420 citations

Double-blind Phase 3, Medicine, Metronomic Therapy +9

Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1

Zike Yang, Yanxia Qi, Nan Lai et al. · Journal of Experimental & Clinical Cancer Research · 2018 · 300 citations · Full text

Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway

Qiaofen Fu, Yan Liu, Yue Fan et al. · Journal of Hematology & Oncology · 2015 · 298 citations · Full text